Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03054-x ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Advances in Therapy, 2025. Verfasst von Jing Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, BRCA2 Protein, BRCA1 Protein, Neoplasms, Second Primary. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: Breast cancer poses significant challenges, especially the increased risk of contralateral breast cancer (CBC) in BRCA1/2 variant carriers. This study systematically reviews and analyzes the effectiveness of secondary risk-reducing strategies for CBC in BRCA1/2 carriers. METHODS: A systematic review and meta-analysis were conducted from January 2000 to December 2023, including RCTs, cohort, or case-control studies involving BRCA carriers with unilateral breast cancer. Random-effects models were used for odds ratios (ORs) on CBC incidence and hazard ratios (HRs) for overall survival (OS), with bias assessed via the Newcastle-Ottawa Scale. RESULTS: A total of 23,840 participants from 26 studies were included. Secondary risk-reducing interventions reduced CBC incidence by 38% [OR 0.62, 95% confidence interval (CI) 0.57-0.68] and improved OS by 45% (HR 0.55, 95% CI 0.46-0.67). Subgroup analyses showed differences by BRCA type, menopausal status, and treatment duration. For BRCA1 carriers, chemotherapy was most effective, while, for BRCA2, it was endocrine therapy. Postmenopausal interventions reduced CBC by 47% (OR 0.53, 95% CI 0.40-0.71), while premenopausal carriers saw a 34% reduction (OR 0.66, 95% CI 0.53-0.82). Tamoxifen's effect diminished over time. CONCLUSION: Secondary prophylaxis reduces CBC and improves OS in BRCA1/2 carriers, with variations by genetic and physiological factors. These findings underscore the need for personalized strategies, considering menopausal status and treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China.
- Macquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Level 5, 75 Talavera Road, Macquarie Park, Sydney, NSW, 2109, Australia.
- Department of Dermatology, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
- Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China. wkming2@cityu.edu.hk.
- Macquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Level 5, 75 Talavera Road, Macquarie Park, Sydney, NSW, 2109, Australia.…
ORCID-Profile: Wai-Kit Ming
Zitieren
APA
Yu, J., Jiang, S., Liu, T., Gao, Y., Ma, X., Fekadu, G., Xia, Y., Parkinson, B., Ming, W. K., & Gu, Y. (2025). Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis. Advances in Therapy. https://doi.org/10.1007/s12325-024-03054-x
Vancouver
Yu J, Jiang S, Liu T, Gao Y, Ma X, Fekadu G, et al. Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis. Advances in Therapy. 2025. doi:10.1007/s12325-024-03054-x
BibTeX
@article{Yu2025,
author = {Yu, Jing and Jiang, Shan and Liu, Taoran and Gao, Yangyang and Ma, Xinyang and Fekadu, Ginenus and Xia, Yunqiu and Parkinson, Bonny and Ming, Wai-Kit and Gu, Yuanyuan},
title = {Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03054-x}
}
EUVIMED